New Johnson & Johnson data shows second shot boosts antibodies and protection against COVID-19 – but one dose is still strong against delta variant

Early clinical trial data released in January 2021 showed that four weeks after the first dose, the Johnson & Johnson single-shot vaccine was 66.3% effective at preventing COVID-19 infection. The initial studies also showed that it was 85% effective at preventing severe or critical disease.

Read moreDetails
Page 25 of 160 1 24 25 26 160

SUBSCRIBE to our NEWSLETTER

[mc4wp_form id=”2384248″]

Don't Miss